Pegaptanib as an adjunctive treatment for complicated neovascular diabetic retinopathy

Archives of Ophthalmology

Volumn 124, Issue 6, 2006, Pages 920-921

  Krzystolik, Magdalena G ^a   Filippopoulos, Theodoros ^b   Ducharme, Joseph F ^b   Loewenstein, John I ^b  

^a Southern New England Retina Associates   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PEGAPTANIB; TRIAMCINOLONE ACETONIDE;

ADULT; ANAMNESIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CASE REPORT; CATARACT EXTRACTION; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG ACTIVITY; GLAUCOMA; GONIOSCOPY; HUMAN; HYPHEMA; LASER COAGULATION; MALE; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; SYMPTOMATOLOGY;

APTAMERS, NUCLEOTIDE; CHEMOTHERAPY, ADJUVANT; DIABETIC RETINOPATHY; GLAUCOMA DRAINAGE IMPLANTS; GLAUCOMA, NEOVASCULAR; GONIOSCOPY; HUMANS; INJECTIONS; IRIS; LENS IMPLANTATION, INTRAOCULAR; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PHACOEMULSIFICATION; POSTOPERATIVE COMPLICATIONS; VITRECTOMY;

EID: 33745042616     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.124.6.920     Document Type: Article

References (4)

1. Jonas JB, Sofker A. Intravitreal triamcinolone acetonide for cataract surgery with iris neovascularization. J Cataract Refract Surg. 2002;28:2040-2041.
2. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
3. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114:66-71.
4. Itakura H, Kishi S, Kotajima N, Murakami M. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy. Ophthalmology. 2004;111:1880-1884.